Recruitment of leukocytes to inflammatory sites is crucial in the pathogenesis of chronic inflammatory diseases. The aim of this study was to investigate if activation of CB 2 cannabinoid receptors would modulate the chemotactic response of human monocytes. 
INTRODUCTION
Cannabinoids modulate immune functions and therefore have a therapeutic potential for the treatment of inflammatory diseases (28, 29, 40) . It is thought that the immunomodulatory effects of cannabinoids are mediated by the cannabinoid receptor 2 (CB 2 ) expressed on immune cells. A growing body of evidence suggests that endocannabinoid signaling plays a critical role in pathophysiological conditions such as haemorrhagic or endotoxic shock (53, 56) , liver cirrhosis (4), fibrosis (24, 52), and ischemic/reperfusion injury (5, 44) , acute heart failure (36), osteoporosis (25, 39, 51) , and cutaneous contact hypersensitivity (26). We have recently provided first experimental evidence for a possible role of CB 2 receptors in atherosclerosis progression (49).
The recruitment of inflammatory cells into the intima is crucial for the development and progression of atherosclerosis (19, 20, 57) . The tethering, rolling, adhesion and transendothelial migration of leukocytes are triggered by local production of chemokines and chemokine receptors as well as adhesion molecules (8) . Cannabinoids have been reported to modulate the migration of various cell types. Thus, it has been reported that treatment of rat macrophages with the synthetic cannabinoid CP55,940 reduced both spontaneous and formyl-metionyl-leucine-phenylalanine (fMLP)-induced chemotaxis (48). The nonpsychoactive marijuana component cannabidiol was shown to inhibit murine macrophage chemotaxis in vitro and in vivo in a CB 2 receptor-dependent manner (47).
Both endogenous as well as synthetic agonists 2-AG, CP55,940 and WIN55,212-2, as well as the CB 2 selective agonists JWH-015 and JWH-133, caused a significant inhibition of the chemokine stromal cell derived factor (SDF)-1/CXCL12-induced and CXCR4-mediated chemotaxis of Jurkat or primary human T cells (11, 15) . In addition, in an experimental autoimmune encephalomyelitis (EAE) mouse model, WIN55,212-2 attenuated leukocyte rolling and adhesion on endothelial cells through the activation of CB 2 receptors (38) . Furthermore, the novel CB 2 1 and CB 2 -dependent manner (6) . The role of CB 2 in this process could be confirmed by additional data obtained with CB 2 agonists, which reduced ICAM-1 and VCAM-1 expression in HCAECs as well as adhesion and transendothelial migration of THP-1 monocytes (43) . Finally, we have shown that THC inhibited murine peritoneal macrophage chemotaxis in response to CCL2 and reduced expression of the chemokine receptor CCR2 on splenocytes (49). These effects were blocked by the CB 2 receptor antagonist SR144528 or when cells from CB 2 knockout mice were used.
In this study, we investigated if CB 2 selective agonists would modulate the migration of human monocytes and thus may have a therapeutic potential in inflammatory conditions such as atherosclerosis.
MATERIALS AND METHODS

Reagents
The CB 2 
Isolation of human monocytes
Human monocytes were isolated from buffy coats of healthy volunteers after informed consent. After centrifugation on Ficoll-Hypaque density gradient, mononuclear cells were collected from the interface and washed with PBS. Then, monocytes were purified from the upper interface of a hypotonic Percoll density gradient (1.129 g/ml). Purified monocytes were resuspended in RPMI 1640 with 25 mM Hepes and 500 ng/ml polymyxin B. The purity of monocytes was determined by flow cytometric analysis (CD14 staining), confirming that at least 85% purity was achieved in all experiments.
Modified Boyden chamber migration assays and checkerboard analysis
To study the effect of cannabinoid treatment on migration, cells were incubated in RPMI containing 25 mM Hepes and 500 ng/ml polymyxin B in presence or absence of different doses of JWH-015 (5, 10, 20 µM) for 12 hours at 37 °C, in a humidified atmosphere with 5% CO 2 . Then, cells were washed three times in PBS and resuspended in chemotaxis medium (RPMI containing 25 mM Hepes and 1% BSA) to test their locomotory response to medium alone, 10 nM CCL2 or 10 nM CCL3. Monocyte chemotaxis was assessed in a 48-well microchemotaxis chamber (NeuroProbe) using a 5 µm pore size, 5-µm-thick polyvinylpyrrolidone-free polycarbonate filter (NeuroProbe). Cells were seeded in the upper wells, while medium or chemoattractant solutions were added to the lower wells. In all conditions, the modified Boyden chamber was incubated for 60 min, at 37 °C in a humidified atmosphere with 5% CO 2 . Then, filters were removed from the chambers and stained with Diff-Quick (Baxter). Each condition was performed in duplicate. The cells of five random oil-immersion fields were counted at 1000× magnification (blinded observer) and the chemotaxis index was calculated from the number of cells migrated to the test samples divided by the number of cells migrated to the medium.
Flow cytometry
Monocytes were cultured at a concentration of 5x10 6 
Cytotoxicity assay
Cell death was determined by quantification of lactate dehydrogenase (LDH) release 
Apoptosis assay
Apoptosis rates of monocytes after 0, 18 and 24 h of treatment with JWH-015 (20 µM), JWH-133 (10 µM), SR147778 (1 µM) or SR144528 (1 µM) were determined via analysis of phophatidylserine externalization using the Annexin V-FITC apoptosis detection kit (MBL).
Immunoblotting
Monocytes were cultured at a concentration of 5x10 6 respectively and expressed as percentages of medium control (defined as 100%).
RT-PCR
Total RNA from 5x10 6 human monocytes was extracted using TRI Reagent 
Real-time RT-PCR
Monocytes were cultured at the concentration of 5x10 6 cells/ml in serum-free RPMI medium containing 25 mM Hepes and 500 ng/ml polymyxin B in the presence or in absence of JWH-015 (5, 10, 20 µM) for 12h, at 37 °C in a humidified atmosphere with 5% CO 2 . Total RNA was extracted using TRI Reagent (MRC, Inc.) and reverse transcribed using the Quantitect kit (Qiagen) according to the manufacturer's instructions. 
Statistical analysis
All data were expressed as mean (±SEM). One-way ANOVA with Bonferroni's post test was performed using GraphPad InStat version 3.05 (GraphPad Software, San Diego, CA). Differences between the P values below 0.05 were considered significant.
RESULTS
The cannabinoid receptor CB 2 is expressed on primary human monocytes
To obtain non-activated primary human monocytes, we performed Ficoll-Percoll density gradient centrifugation. We first confirmed the presence of CB 2 cannabinoid receptors on freshly isolated monocytes and found high expression levels on the cell surface (Fig. 1A ).
In addition, CB 2 mRNA expression in monocytes was detected by RT PCR (Fig. 1B) .
Interestingly, we observed a significant increase of CB 2 surface expression when monocytes were cultured for up to 24h (Fig. 1C) . The presence of CB 2 agonist JWH-015 (20 µM) did not change the observed modulation. To validate our experimental conditions, we tested the cell viability and extend of apoptosis in monocytes treated with cannabinoids or antagonists for up to 24h. We found an increasing percentage of dead and apoptotic cells in monocyte cultures (Fig. 2) , comparable to the magnitudes previously reported (21, 37) . The increase of cell death was due to the culture conditions in serum-free medium, which was performed to avoid the interference with serum factors.
Importantly, treatment with cannabinoids and/or antagonists did not affect cell viability and apoptosis rates (Fig. 2) . In none of the experimental conditions, we observed an increased LDH release as compared to untreated cells after 12, 18 and 24 h of incubation (data not shown).
Treatment with the CB 2 agonist JWH-015 reduces monocyte migration to CCL2 and CCL3 by reducing chemokine receptor expression
We assessed monocyte migration in response to CCL2 and CCL3 with the modified Boyden chamber system. Pretreatment with 5 to 20 µM of the CB 2 agonist JWH-015 for 12h significantly reduced the chemotactic response to CCL2 and CCL3 in a dosedependent manner (Fig. 3A) . The maximum inhibition was observed at 10 to 20 µM JWH-015. We next analyzed the effect of JWH-015 on the expression of the chemokine receptors which bind CCL2 and CCL3. Treatment of monocytes with JWH-015 for 18h
inhibited the surface expression of chemokine receptor CCR2 and, to a lesser extend, CCR1 at a concentration of 10 to 20 µM (Fig. 3B , E, F). This effect was associated with significantly reduced CCR2 mRNA levels as determined after 12h of JWH-015 treatment (Fig. 3C) . We also observed a marked, but not significant reduction of CCR1 mRNA levels. Pretreatment with the CB 2 antagonist SR144528 reversed the effect of JWH-015 on surface CCR2 and CCR1 expression, while the CB 1 antagonist SR147778 had no effect (Fig. 3D) . It is of note that co-treatment of cells with JWH-015 and CB 2 antagonist SR144528 induced a marked, but not significant increase of chemokine receptor expression as compared to untreated cells. Treatment with CB 1 antagonist SR147778 or CB 2 antagonist SR144528 alone did not have a significant effect. Similar to JWH-015, incubation with the CB 2 agonist JWH-133 at 10 µM also reduced CCR2 and CCR1 surface expression (Fig. 3D) , while the vehicle DMSO alone did not affect mRNA or surface expression of the chemokine receptors (data not shown).
Treatment with JWH-015 modulates ICAM-1 expression on human monocytes
We further investigated the effect of JWH-015 on the expression of ICAM-1 which is implicated in monocyte recruitment. The basal expression of ICAM-1, which was strongly expressed on all monocytes, was significantly (1.44 fold) enhanced after 24h of incubation with IFN-! (Fig. 4A, B) . When JWH-015 (20 µM) or JWH-133 (10 µM) was added during stimulation, the IFN-!-induced activation was significantly inhibited. The 
JWH-015 induces chemotaxis of human monocytes
Because various cannabinoids have been reported to chemoattract different cell types, we next tested the ability of JWH-015 and JWH-133 to induce migration of freshly isolated monocytes. The number of cells migrating to the respective cannabinoid was increased as compared to the medium control, with a significant effect observed at 20 µM JWH-015
(chemotaxis index of 1.98±0.26) or 10 µM JWH-133, respectively (chemotaxis index of 1.98 ± 0.2; Fig. 5A ). Pretreatment with the CB 2 antagonist SR144528 inhibited the effect of JWH-015 and JWH-133, while the CB 1 antagonist SR147778 had no effect (Fig. 5B ).
To distinguish if the migration was due to induction of chemotaxis or chemokinesis, we performed a checkerboard analysis with increasing concentrations of JWH-015 above and below the filter. We found a directed migration versus a gradient across the filter, indicating that JWH-015 induced chemotaxis rather than random chemokinesis (Fig. 5C ).
JWH-015 cross-desensitizes monocytes for migration to CCL2 and CCL3
To investigate the chemotactic effect of JWH-015 in presence of a chemokine gradient, freshly isolated monocytes were seeded with increasing concentrations of JWH-015 to the upper well and chemoattracted with CCL2 or CCL3, respectively. We found that the migration to both CCL2 and CCL3 was significantly reduced in the presence of 10 to 20
µM JWH-015, suggesting that JWH-015 cross-desensitizes monocytes for migration to these chemokines (Fig. 5D ).
The JWH-015 mediated modulation of monocyte migration involves PI3K/Akt and ERK
1/2, but not p38 MAPK signaling pathways
To investigate if the JWH-015 mediated effects on chemokine receptor expression and migration were dependent on distinct kinase signaling pathways, we performed experiments with selective kinase inhibitors for PI3K and MEK 1/2 (the activator of ERK 1/2) as well as p38 MAPK. Pretreatment with the PI3K inhibitor LY2940002 or the MEK 1/2 inhibitor PD98059 abolished the inhibition of CCR2 expression in response to JWH-015 (Fig. 6A) . Conversely, pretreatment with the p38 MAPK inhibitor SB203580 had no effect. Similar effects of the kinase inhibitors were observed on CCR1 expression; however, the differences were not significant. To study if JWH-015-induced migration was dependent on the same downstream pathways than the above described effect on chemokine receptor expression, we performed migration assays after pretreatment with kinase inhibitors. We found that both the PI3K inhibitor LY2940002 and the MEK 1/2 inhibitor PD98059 inhibited the chemotactic response to JWH-015, whereas the p38 MAPK inhibitor SB203580 had no effect (Fig. 6B) . To confirm these findings, we determined the effect of JWH-015 on kinase activation by western blot analysis (6C, D).
CCL2 was used as a positive control for kinase activation in parallel experiments. We found increased phosphorylation of the direct downstream kinases of PI3K and MEK 1/2, namely Akt and ERK 1/2. However, we also determined a significant activation of p38 MAPK, as shown on representative blots in Fig. 6C and densitometric quantification of 4 to 5 individual experiments (Fig. 6D ). JWH-015 induces monocyte migration by its own chemotactic properties and is able to cross-desensitize the migration in response to CCL2 and CCL3.
DISCUSSION
Our data confirming high levels of CB 2 expression on human monocytes (by using flow cytometry analysis and RT-PCR) suggest an important role for CB 2 in different monocyte functions. We first studied the effect of JWH-015 on CCL2 and CCL3 induced migration, two major chemokines expressed at inflammatory sites which trigger monocyte recruitment (10). The observed reduction of monocyte migration after 12h treatment with JWH-015 is explained by the reduced expression of CCR2 and, to a lesser extent, CCR1.
We focused on the principal receptors involved in monocyte locomotion, such as CCR2, the corresponding receptor for CCL2, and CCR1, the receptor for CCL3. Although CCL3 is also capable of binding CCR5, this receptor is expressed at low levels on human monocytes and is considered less important for monocyte migration to CCL3 (58 and CB 1 , respectively) (42). However, the effective doses for inhibition were much higher than the K i value for CB 2 , which may also lead to activation of CB 1 receptors which are also expressed at considerable levels on monocytes (13 for the observed effects has been previously described by Bouaboula and co-workers (7).
In stably CB 2 -transfected rodent cell line, the CB 2 antagonist SR144528 was shown to block not only the activity of CB2, but also the MAPK activity of other G-protein- In addition to the long term effects (after 12-24h) of JWH-015 on monocyte migration, we also investigated short term actions (after a few minutes) of JWH-015 on the monocytes. We found that JWH-015 itself is chemoattractant for monocytes, an effect that has been previously reported for various cannabinoids on other cell types (11, 15, Similar discrepancies between kinase activation and their involvement in cellular functions have been previously described. Indeed, it has been shown that the PI3K/Akt and MEK1/2 pathways were not or only partially involved in monocyte chemotaxis in response to CCL2 and CCL3, although these two chemokines were capable of activating both PI3K/Akt and ERK 1/2 (2, 3, 12, 55) . On the other hand, CCL2 was shown to activate p38 MAPK, and inhibitors of p38 MAPK induced a substantial inhibition of 21 CCL2 induced migration (2, 3, 9) . Our data suggest two potential targets, namely PI3K/Akt and ERK 1/2, selectively involved in JWH-015 mediated short term and long term effects on monocyte migration, without involvement of classical p38 MAPKdependent intracellular pathways (Fig. 6) . However, while JWH-015 induces p38 MAPK phosphorylation, the potential downstream targets of p38 signaling in our model remain unclear.
In conclusion 
